Since 1997, finasteride has been marketed under many trade names (Propecia is the most prominent) for reversing the effects of male pattern hair loss. But before that—in 1992—it was approved by the US Food and Drug Administration for treating benign prostatic hyperplasia (enlarged prostate gland) and prostate cancer. In 2008, the Swedish Medical Academy advised users that finasteride may have persistent sexual side effects.
Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.
Molecule of the Week needs your suggestions!
If your favorite molecule is not in our archive, please send us a message. The molecule can be notable for its current or historical importance or for any quirky reason. Thank you!
Stay Ahead of the Chemistry Curve
Learn how ACS can help you stay ahead in the world of chemistry.